Tavira Therapeutics SRL
1.9 FTETavira Therapeutics reported total assets of 863,682 € at the end of the 2025 financial year (annual accounts filed with the NBB on 03 Jul 2026), with 1.9 full-time equivalent.
By total assets for 2025, Tavira Therapeutics ranks in the top half of the 994 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Tavira Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
The full file covers 2 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Tavira Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 03 Jul 2026
- Year ended 31 Dec 2024filed on 22 May 2025
Tavira Therapeutics's financial analysis
- Solvency-8.4%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Tavira Therapeutics
Tavira Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0802.591.262
- VAT number
- BE0802591262
- Peppol
- Registered · 0208:0802591262 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Jun 2023
- Registered office
- 3001 Leuven
- Size
- Micro · 1.9 FTE
- Latest accounts
- 2025 · filed on 03 Jul 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
Tavira Therapeutics (SRL) has been based in Leuven since 2023, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net loss of 567,681 € and equity of −72,543 €; its revenue is not published. With 1.9 full-time equivalents, it is a micro-enterprise by headcount.
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Tavira Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- MSI-Dfat EU Research and experimental development on natural sciences and engineering Jodoigne · balance sheet €1.08m
- Afems Research and experimental development on natural sciences and engineering Auderghem · balance sheet 863,868 €
- Convert Pharmaceuticals Research and experimental development on natural sciences and engineering Liège · balance sheet 941,204 €
- Emicap Research and experimental development on natural sciences and engineering Kortrijk · balance sheet 941,206 €
- Gynaia Belgium Research and experimental development on natural sciences and engineering Leuven · balance sheet €1.00m
- Digital Dental Design Robotics Research and experimental development on natural sciences and engineering Waterloo · balance sheet 676,178 €
- A-membranes Research and experimental development on natural sciences and engineering Leuven · balance sheet 633,856 €
- Sciempath Bio Research and experimental development on natural sciences and engineering Braine-l'Alleud · balance sheet 608,601 €
Frequently asked questions about Tavira Therapeutics
What is the revenue of Tavira Therapeutics?
Tavira Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Tavira Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0802591262 for Tavira Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0802.591.262.
Where is the registered office of Tavira Therapeutics?
According to the CBE register, the registered office of Tavira Therapeutics is in 3001 Leuven.
What is the equity of Tavira Therapeutics?
At the close of the 2025 financial year, the equity of Tavira Therapeutics amounts to -72,543 €, a solvency of -8.4% of total assets.
How many people work at Tavira Therapeutics?
1.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Tavira Therapeutics?
The register lists 5 active mandates at Tavira Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Tavira Therapeutics within its sector?
By total assets for 2025, Tavira Therapeutics ranks in the top half of the 994 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of Tavira Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →